secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001082554-24-000049
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics Q3 revenue $748.9M (+23% YoY); net income $309.1M (+16%)
----------------------------------------------------------------------------

- Total revenues $748.9M, +23% YoY; net income $309.1M ($6.39 diluted EPS) vs $267.6M ($5.38).
- Tyvaso product revenues $433.8M, +33% YoY driven by Tyvaso DPI uptake and PH-ILD expansion.
- Accrued $65.1M litigation liability related to ongoing Sandoz patent case; final judgment pending.
- Completed $1B accelerated share repurchase; repurchased ~3.55M shares during Q2-Q3 2024.
- Management notes record revenue sixth straight quarter; Tyvaso remains key growth driver.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255424000049/0001082554-24-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255424000049/uthr-20241030.htm
  HTML page:      https://secwatch.observer/filing/0001082554-24-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer